Skip to Content
A home for paediatricians. A voice for children and youth.
CPS

Management of febrile neutropenia in immunocompetent children and youth

Posted: Jun 29, 2023


The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Principal author(s)

Marie-Pier Lirette MBChB, Nicola Wright MD, Evelyne D. Trottier MD, Carolyn E Beck MD  , Acute Care Committee

Paediatr Child Health 28(5):324–326.

Abstract

Febrile neutropenia is a common clinical presentation in children that can be associated with invasive bacterial infection (IBI). However, in otherwise healthy children and youth with fever and neutropenia, the risk for IBI is low, with most cases being caused by viral infections. Well-appearing, non-oncologic, and presumed immunocompetent children aged 6 months to 18 years experiencing a first episode of neutropenia, with no additional risk factors, typically do not require empiric antibiotics. However, a thorough assessment, including complete history and physical exam, is indicated, and a blood culture should be performed when the absolute neutrophil count is <0.5 x 109/L. Close follow-up, a repeat complete blood count, and strong anticipatory guidance are recommended.

Keywords: Fever; Invasive bacterial infection; Neutropenia; Paediatric

Background

Febrile neutropenia in paediatrics is commonly encountered from primary through tertiary care. Clinical presentation can vary from mild transient illness to severe life-threatening conditions[1]. Clinicians are most concerned about the risk of invasive bacterial infections (IBI) such as bacteremia and meningitis, particularly when neutropenia is severe. Immunosuppressed children and youth, such as those with malignancy, are at high risk of IBI, with a bacterial pathogen identified in up to 30% of cases[2][3]. There is limited information regarding the rates of IBI in otherwise healthy paediatric patients with febrile neutropenia[4][5] though the rate of IBI does not appear to be increased compared to non-neutropenic children, and positive blood cultures are rare[1][6]-[12]. The most common causes of neutropenia in well-appearing, immunocompetent patients older than 3 months are viral illnesses[1][9]-[12] or common bacterial infections[7][8]. Other etiologies may include recent antibiotic use, anticonvulsant therapy, autoimmune disorders such as autoimmune neutropenia, and vitamin B12 or folate deficiency. In most, the neutropenia is transient and resolves within a few weeks[6]-[8]. Established guidelines recommend intravenous (IV) antibiotics and hospital admission for most paediatric oncologic patients with febrile neutropenia. Given the paucity of evidence in the non-oncologic population, recommendations for healthy children with neutropenia are less established.

This practice point proposes that less aggressive management is often appropriate in otherwise healthy children and youth with no additional risk factors[4]-[7][13]. It applies to well-appearing, non-oncologic, and presumed immunocompetent individuals 6 months to 18 years of age who experience a first episode of febrile neutropenia. Management aims to ensure safe patient care while contributing to resource stewardship, considers illness severity and risk tolerance, and emphasizes shared decision-making between clinicians and parents or caregivers. Supplementary Figure 1 summarizes best practice points.

Definitions

The conventional definition of neutropenia is an absolute neutrophil count (ANC) <1.5 x 10 /L, including all neutrophils, bands, myelocytes, and metamyelocytes. Severe neutropenia is typically defined as an ANC <0.5 x 10 /L, moderate neutropenia as an ANC 0.5 to <1.0 x 10 /L, and mild neutropenia as an ANC 1.0 to <1.5 x 10 /L ).

A temperature measurement >38°C is typically considered a fever[15]. The Infectious Diseases Society of America defines fever in neutropenic oncologic patients as a single oral temperature ≥38.3°C or a temperature ≥38°C sustained over 1 hour[16]. However, there is no clear definition of fever in presumed immunocompetent children with neutropenia. Rectal temperature-taking is not recommended for children with severe neutropenia. Axillary or oral measurements (in cooperative children older than 5 years of age) should be obtained[15]

Best practice points

Assessment for IBI

  • Perform a complete history and physical examination, paying particular attention to risk factors for IBI (Table 1). Children with any one risk factor are considered high risk, and individualized care is warranted in such cases.
  • Document general state and vital signs, including a repeat temperature if a measurement has not been taken recently. Ill-appearing children with neutropenia are at higher risk for IBI. Assess the ABCs—airway, breathing, and circulation—and stabilize[17] as needed. Ensure that a recent complete blood count (CBC) and differential, reticulocytes, and a peripheral blood smear, have been obtained in all patients with suspected or known neutropenia. For individuals with thrombocytopenia, lymphopenia, or unexplained anemia in addition to neutropenia, consider other etiologies such as leukemia or bone marrow failure.

Children and youth with neutropenia AT RISK for IBI (Table 1):

  • If ill-appearing, obtain blood culture and do not delay starting broad-spectrum empiric antibiotics. Refer to this CPS practice point on the diagnosis and management of sepsis for guidance[18].
  • If well-appearing, management should be individualized, preferably in consultation with a paediatric specialist. IV antibiotics are typically required, and these children are either admitted or discharged home with close out-patient follow-up.

Children and youth with isolated neutropenia, NOT AT RISK for IBI:

  • Individuals with an ANC >1.0 x 10/L can be managed as per those with normal ANC.
  • Paediatric patients with an ANC 0.5 to <1.0 x 10 /L do not routinely require empiric antibiotics. Their health care provider (HCP) should order a repeat CBC in 1 to 3 months[5][7].
  • For individuals with severe neutropenia (ANC <0.5 x 10 /L):
    • Ensure peripheral blood culture has been obtained. Consider performing a urinalysis or urine culture in incontinent children (generally <24 months old), and for those with symptoms or risk factors for urinary tract infection (UTI)[19]. Based on clinical presentation, also consider investigations such as chest x-ray or respiratory viral polymerase chain reaction testing.
    • Well-appearing children with an ANC <0.5 x 10 /L and no risk factors for IBI (Table 1) are considered low risk. Empiric antibiotics are usually not indicated, but may be considered when the child’s ANC is 0 to 0.2 x 10 /L. Organize close out-patient follow-up within 24 to 48 hours. Provide clear discharge instructions and consider consulting with a paediatrician or paediatric hematologist.
    • Out-patient referral to a paediatrician or paediatric hematologist should be organized at 4 to 6 weeks if a child’s ANC remains <0.5 x 10 /L, and earlier if interim evaluation reveals other cell line abnormalities. Until severe neutropenia resolves, a child who develops a new fever should be assessed urgently by an HCP.
    • Educate parents, alternate care providers, and the patient (if appropriate) before discharge. They should understand the signs and symptoms of sepsis (e.g., pallor, lethargy or low level of consciousness, confusion, persistent vomiting, persistent fever) and the reasons for seeking urgent medical attention.
 
 

Acknowledgements

The authors wish to thank Charlotte Grandjean-Blanchet, MD, FRCPC, CHU Sainte-Justine, for her careful review of this practice point, which has also been reviewed by the Community Paediatrics and Infectious Diseases and Immunization Committees of the Canadian Paediatric Society, and by the CPS Paediatric Emergency Medicine Section Executive.


Members: Carolyn E. Beck MD, Kevin Chan MD (Chair), Kimberly Dow MD (Board Representative), Karen Gripp MD (Past Member), Marie-Pier Lirette MBChB (Resident Member), Jonathan Sniderman MD, Evelyne D. Trottier MD, Troy Turner MD

Liaisons: Laurel Chauvin-Kimoff MD (Past Chair 2012-2019), CPS Paediatric Emergency Medicine Section; Sidd Thakore MD, CPS Hospital Paediatrics Section

Principal authors: Marie-Pier Lirette MBChB, Nicola Wright MD, Evelyne D. Trottier MD, Carolyn E Beck MD  


References

  1. Wittmann O, Rimon A, Scolnik D, Glatstein M. Outcomes of immunocompetent children presenting with fever and neutropenia. J Emerg Med 2018;54(3):315–19.
  2. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007;45(10):1296–304.
  3. Lakshmaiah KC, Malabagi AS, Shetty R, Sinha M, Jayashree RS. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians 2015;7(2):116–20.
  4. Sung L, Johnston DL. Approach to febrile neutropenia in the general paediatric setting. Paediatr Child Health 2007;12(1):19–21.
  5. Knight K. Question 2: Unexpected neutropenia in a febrile, but immunocompetent, child. Arch Dis Child 2015;100(11):1093–95.
  6. Segel GB, Halterman JS. Neutropenia in pediatric practice. Pediatr Rev 2008;29(1):12–24.
  7. Alexandropoulou O, Kossiva L, Haliotis F, et al. Transient neutropenia in children with febrile illness and associated infectious agents: 2 years’ follow-up. Eur J Pediatr 2013;172(6):811–19.
  8. Melendez E, Harper MB. Risk of serious bacterial infection in isolated and unsuspected neutropenia. Acad Emerg Med 2010;17(2):163–67.
  9. Barg AA, Kozer E, Mordish Y, Lazarovitch T, Kventsel I, Goldman M. The risk of serious bacterial infection in neutropenic immunocompetent febrile children. J Pediatr Hematol Oncol 2015;37(6):e347–51.
  10. Pascual C, Trenchs V, Hernández-Bou S, Català A, Valls AF, Luaces C. Outcomes and infectious etiologies of febrile neutropenia in non-immunocompromised children who present in an emergency department. Eur J Clin Microbiol Infect Dis 2016;35(10):1667–72.
  11. Hindie J, Pastore Y, Nguyen U, Cummins-McManus B, Tapiero B, Hervouet-Zeiber C. 14: Severe neutropenia with fever in previously healthy children: Do they all need broad-spectrum antibiotics? Paediatr Child Health 2014;19(6):e40–e41.
  12. Jade H, Hervouet-Zeiber C, Nguyen UP, Cummins-McManus B, Tapiero B, Pastore Y. The risk of bacteremia in previously healthy children presenting with severe neutropenia and fever. Ann Pediatr Res. 2018;2(1):1010.
  13. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012;30(35):4427–38.
  14. Walkovich K, Boxer LA. How to approach neutropenia in childhood. Pediatr Rev 2013;34(4):173-84.
  15. Caring for Kids, Community Paediatrics Committee. Fever and temperature taking. Canadian Paediatric Society, 2022: https://www.caringforkids.cps.ca/handouts/health-conditions-and-treatments/fever_and_temperature_taking.
  16. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52(4):e56–93.
  17. Dieckmann RA, Brownstein D, Gausche-Hill M. The pediatric assessment triangle: A novel approach for the rapid evaluation of children. Pediatr Emerg Care 2010;26(4):312-15.
  18. Farrell CA; Canadian Pediatric Society, Acute Care Committee. Diagnosis and management of sepsis in the paediatric patient. Canadian Paediatric Society, 2020: https://www.cps.ca/en/documents/position/diagnosis-and-management-of-sepsis-in-the-paediatric-patient.
  19. Robinson JL, Finlay JC, Lang ME, Bortolussi R; Canadian Pediatric Society, Infectious Diseases and Immunization Committee. Urinary tract infection in infants and children: Diagnosis and management. Paediatr Child Health. 2014;19(6):315–25: https://www.cps.ca/en/documents/position/urinary-tract-infections-in-children.

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.

Last updated: May 7, 2024